These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33853539)

  • 1. Phase I dose-escalation oncology trials with sequential multiple schedules.
    Günhan BK; Weber S; Seroutou A; Friede T
    BMC Med Res Methodol; 2021 Apr; 21(1):69. PubMed ID: 33853539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bayesian time-to-event pharmacokinetic model for phase I dose-escalation trials with multiple schedules.
    Günhan BK; Weber S; Friede T
    Stat Med; 2020 Nov; 39(27):3986-4000. PubMed ID: 32797729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials.
    Dinart D; Fraisse J; Tosi D; Mauguen A; Touraine C; Gourgou S; Le Deley MC; Bellera C; Mollevi C
    BMC Med Inform Decis Mak; 2020 Jun; 20(1):134. PubMed ID: 32580715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-stage subgroup-specific time-to-event (2S-Sub-TITE): An adaptive two-stage time-to-toxicity design for subgroup-specific dose finding in phase I oncology trials.
    McGovern A; Chapple AG; Ma C
    Pharm Stat; 2022 Nov; 21(6):1138-1148. PubMed ID: 35560864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
    Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
    Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method.
    North B; Kocher HM; Sasieni P
    BMC Cancer; 2019 Jun; 19(1):632. PubMed ID: 31242873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practicalities in running early-phase trials using the time-to-event continual reassessment method (TiTE-CRM) for interventions with long toxicity periods using two radiotherapy oncology trials as examples.
    van Werkhoven E; Hinsley S; Frangou E; Holmes J; de Haan R; Hawkins M; Brown S; Love SB
    BMC Med Res Methodol; 2020 Jun; 20(1):162. PubMed ID: 32571298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities.
    Polley MY
    Stat Med; 2011 Jul; 30(17):2130-43. PubMed ID: 21590790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses.
    Ursino M; Biard L; Chevret S
    Biom J; 2022 Dec; 64(8):1486-1497. PubMed ID: 34729815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials.
    Yuan Y; Lin R; Li D; Nie L; Warren KE
    Clin Cancer Res; 2018 Oct; 24(20):4921-4930. PubMed ID: 29769209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics.
    Gerard E; Zohar S; Thai HT; Lorenzato C; Riviere MK; Ursino M
    Biometrics; 2022 Mar; 78(1):300-312. PubMed ID: 33527351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
    Takeda K; Morita S; Taguri M
    Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TITE-gBOIN: Time-to-event Bayesian optimal interval design to accelerate dose-finding accounting for toxicity grades.
    Takeda K; Xia Q; Liu S; Rong A
    Pharm Stat; 2022 Mar; 21(2):496-506. PubMed ID: 34862715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
    Normolle D; Lawrence T
    J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method.
    Bayar MA; Ivanova A; Le Teuff G
    Comput Methods Programs Biomed; 2019 Jul; 176():211-223. PubMed ID: 31200907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
    Gerke O; Siedentop H
    Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
    Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
    Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An extended Bayesian semi-mechanistic dose-finding design for phase I oncology trials using pharmacokinetic and pharmacodynamic information.
    Yang C; Li Y
    Stat Med; 2024 Feb; 43(4):689-705. PubMed ID: 38110304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subgroup-specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combination.
    Chapple AG; Thall PF
    Pharm Stat; 2018 Nov; 17(6):734-749. PubMed ID: 30112806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.